Work

Elinzanetant (NT-814): a novel, non-hormonal dual NK-1,3 receptor antagonist for the treatment of vasomotor symptoms - key findings from the Phase 2 SWITCH-1 study

Year: 2021

Type: article

Source: Maturitas

DOI: 10.1016/j.maturitas.2021.08.018

Authors: Nicholas Panay, Richard A Anderson, Hadine Joffe, Cecilia Caetano, Steve Pawsey, Christian Seitz, Lineke Zuurman, James Simon

Institutions: Queen Charlotte's and Chelsea Hospital, Imperial College London, MRC Centre for Reproductive Health, University of Edinburgh, Brigham and Women's Hospital, Harvard University, Bayer (Switzerland), NeRRe Therapeutics (United Kingdom), Bayer (Germany), George Washington University

Language: English

Topic: Menopause: Health Impacts and Treatments

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3206616195

FWCI:

Cites:

Cited by:

Related to: 10